• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于潜在抗癌治疗的取代1,4-萘醌:细胞毒性作用及新类似物的QSAR导向设计

Substituted 1,4-naphthoquinones for potential anticancer therapeutics: cytotoxic effects and QSAR-guided design of new analogs.

作者信息

Prachayasittikul Veda, Mandi Prasit, Pingaew Ratchanok, Prachayasittikul Supaluk, Ruchirawat Somsak, Prachayasittikul Virapong

机构信息

Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.

Department of Community Medical Technology, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.

出版信息

Comput Struct Biotechnol J. 2025 Jul 25;27:3492-3509. doi: 10.1016/j.csbj.2025.07.040. eCollection 2025.

DOI:10.1016/j.csbj.2025.07.040
PMID:40808802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12345971/
Abstract

1,4-Naphthoquinone is a promising pharmacophore in drug discovery due to its unique redox reactive nature and wide-ranging bioactivities. Herein, a series of 1,4-naphthoquinones (-) were investigated for their anticancer activities against 4 cancer cell lines (i.e., HepG2, HuCCA-1, A549, and MOLT-3). Compound was found to be the most potent and selective anticancer agent against all tested cell lines (IC = 0.15 - 1.55 μM, selectivity index = 4.14 - 43.57). QSAR modelling was performed to elucidate key structural features influencing activities against four cancer cell lines. Four QSAR models were successfully constructed using multiple linear regression (MLR) algorithm providing good predictive performance (R: training set = 0.8928-0.9664; testing set = 0.7824-0.9157; RMSE: training set = 0.1755-0.2600; testing set = 0.2726-0.3748). QSAR models suggested that the potent anticancer activities of these naphthoquinones were mainly influenced by polarizability (MATS3p and BELp8), van der Waals volume (GATS5v, GATS6v, and Mor16v), mass (G1m), electronegativity (E1e), and dipole moment (Dipole and EEig15d) as well as ring complexity (RCI) and shape of the compound (SHP2). The models were further applied for guiding the design and predicting activities of an additional set of 248 structurally modified compounds in which the ones with promising predicted activities were highlighted for potential further development. Additionally, pharmacokinetic profiles and possible binding modes towards potential biological targets of the compounds were virtually assessed. Structure-activity relationship analysis was also conducted to highlight key structural features beneficial for further successful design of the related naphthoquinones.

摘要

1,4-萘醌因其独特的氧化还原反应性质和广泛的生物活性,在药物研发中是一种很有前景的药效基团。在此,研究了一系列1,4-萘醌(-)对4种癌细胞系(即HepG2、HuCCA-1、A549和MOLT-3)的抗癌活性。发现化合物对所有测试细胞系都是最有效的和选择性的抗癌剂(IC = 0.15 - 1.55 μM,选择性指数 = 4.14 - 43.57)。进行了定量构效关系(QSAR)建模以阐明影响对四种癌细胞系活性的关键结构特征。使用多元线性回归(MLR)算法成功构建了四个QSAR模型,其具有良好的预测性能(R:训练集 = 0.8928 - 0.9664;测试集 = 0.7824 - 0.9157;RMSE:训练集 = 0.1755 - 0.2600;测试集 = 0.2726 - 0.3748)。QSAR模型表明,这些萘醌的强效抗癌活性主要受极化率(MATS3p和BELp8)、范德华体积(GATS5v、GATS6v和Mor16v)、质量(G1m)、电负性(E_{1e})、偶极矩(Dipole和EEig15d)以及化合物的环复杂性(RCI)和形状(SHP2)影响。这些模型进一步用于指导另外248种结构修饰化合物的设计和预测活性,其中突出显示了具有有前景的预测活性的化合物以供潜在的进一步开发。此外,虚拟评估了化合物的药代动力学概况以及对潜在生物靶点的可能结合模式。还进行了构效关系分析以突出有利于相关萘醌进一步成功设计的关键结构特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/dbc5cdbab20c/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/da2249fbde7f/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/47f4d694ec36/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/396265103bfd/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/18643361fadd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/28ed482d5d5e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/a2692c1c0237/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/20da894f5166/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/5a7f94e9a16d/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/dbc5cdbab20c/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/da2249fbde7f/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/47f4d694ec36/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/396265103bfd/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/18643361fadd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/28ed482d5d5e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/a2692c1c0237/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/20da894f5166/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/5a7f94e9a16d/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e618/12345971/dbc5cdbab20c/gr8.jpg

相似文献

1
Substituted 1,4-naphthoquinones for potential anticancer therapeutics: cytotoxic effects and QSAR-guided design of new analogs.用于潜在抗癌治疗的取代1,4-萘醌:细胞毒性作用及新类似物的QSAR导向设计
Comput Struct Biotechnol J. 2025 Jul 25;27:3492-3509. doi: 10.1016/j.csbj.2025.07.040. eCollection 2025.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
4
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗:一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
5
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Exploring Type II Diabetes Inhibitors from Genus Daphne Plant-species: An Integrated Computational Study.探索瑞香属植物物种中的II型糖尿病抑制剂:一项综合计算研究。
Comb Chem High Throughput Screen. 2025;28(8):1413-1442. doi: 10.2174/0113862073262227231005074024.

本文引用的文献

1
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis.炎症在癌症中的作用:肿瘤起始、进展和转移的机制
Cells. 2025 Mar 25;14(7):488. doi: 10.3390/cells14070488.
2
Cell cycle dysregulation in cancer.癌症中的细胞周期失调
Pharmacol Rev. 2025 Mar;77(2):100030. doi: 10.1016/j.pharmr.2024.100030. Epub 2024 Dec 24.
3
Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.连接表观基因组学与肿瘤免疫代谢:分子机制及治疗意义
Mol Cancer. 2025 Mar 8;24(1):71. doi: 10.1186/s12943-025-02269-y.
4
Inflammation in cancer: therapeutic opportunities from new insights.癌症中的炎症:新见解带来的治疗机遇
Mol Cancer. 2025 Feb 24;24(1):51. doi: 10.1186/s12943-025-02243-8.
5
Design, synthesis and pharmacological evaluation of 1,4-naphthoquinone- 1,2,3-triazole hybrids as new anticancer agents with multi-kinase inhibitory activity.1,4-萘醌-1,2,3-三唑杂化物作为具有多激酶抑制活性的新型抗癌剂的设计、合成及药理评价
Sci Rep. 2025 Feb 24;15(1):6639. doi: 10.1038/s41598-025-87483-w.
6
Design, synthesis, and cytotoxic activity of 2-amino-1,4-naphthoquinone-benzamide derivatives as apoptosis inducers.设计、合成及 2-氨基-1,4-萘醌-苯甲酰胺衍生物的细胞毒性活性作为诱导细胞凋亡。
Sci Rep. 2024 Nov 8;14(1):27302. doi: 10.1038/s41598-024-78468-2.
7
DockThor-VS: A Free Platform for Receptor-Ligand Virtual Screening.DockThor-VS:一个免费的受体配体虚拟筛选平台。
J Mol Biol. 2024 Sep 1;436(17):168548. doi: 10.1016/j.jmb.2024.168548. Epub 2024 Mar 20.
8
In Vitro and In Vivo Biological Evaluation of Novel 1,4-Naphthoquinone Derivatives as Potential Anticancer Agents.新型1,4-萘醌衍生物作为潜在抗癌剂的体外和体内生物学评价
ChemMedChem. 2024 Dec 16;19(24):e202400495. doi: 10.1002/cmdc.202400495. Epub 2024 Oct 15.
9
Historical Perspective and Current Trends in Anticancer Drug Development.抗癌药物研发的历史回顾与当前趋势
Cancers (Basel). 2024 May 15;16(10):1878. doi: 10.3390/cancers16101878.
10
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia.表观遗传调节因子EP300/CREBBP是MLL重排急性髓系白血病中很有前景的治疗靶点。
Cell Death Discov. 2024 May 1;10(1):206. doi: 10.1038/s41420-024-01940-5.